Table 3.
Phenotypea | Response to PPSV23, age >6 years | Response to PPSV23, age <6 years | Notes |
---|---|---|---|
Severe | ≤2 protective titers (≥1.3 μg/mL) | ≤2 protective titers (≥1.3 μg/mL) | Protective titers present are low |
Moderate | <70% of serotypes are protective (≥1.3 μg/mL) | <50% of serotypes are protective (≥1.3 μg/mL) | Protective titers present to ≥3 serotypes |
Mild | Failure to generate protective titers to multiple serotypes or failure of a twofold increase in 70% of serotypes | Failure to generate protective titers to multiple serotypes or failure of a twofold increase in 50% of serotypes | Twofold increases assume a pre-vaccination titer of <4.4–10.3 μg/mL, depending on the pneumococcal serotype |
Memory | Loss of response within 6 months | Loss of response within 6 months | Adequate initial response to ≥50% of serotypes in children <6 years of age and ≥70% in those >6 years of age |
aAll phenotypes assume a history of infection.
*Reprinted from J Allergy Clin Immunol, 130, Orange J, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology, S1-24, Copyright (2012), with permission from Elsevier.